NCT01068977View on ClinicalTrials.gov

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Solid Cancers
Interventions
DRUG

bevacizumab

Repeating intravenous dose

DRUG

MetMAb

Repeating escalating intravenous dose

DRUG

MetMAb

Repeating intravenous dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY